Amoy Diagnostics (AmoyDx), a leading player in China’s molecular diagnostics sector, has achieved a significant regulatory milestone with the approval of its c-Met gene amplification detection kit. The National Medical Products Administration (NMPA) recently granted the medical device registration certificate for the kit, which utilizes Fluorescence In Situ Hybridization (FISH) technology to identify specific genetic drivers in non-small cell lung cancer (NSCLC) patients.
The clinical significance of this tool lies in its role as a companion diagnostic for Savolitinib, a MET inhibitor co-developed by AstraZeneca and HUTCHMED. By identifying patients with c-Met gene amplification—a common mechanism of resistance to other targeted therapies—the kit allows oncologists to precisely tailor treatments. This synergy between diagnostic testing and pharmaceutical intervention is a cornerstone of the modern precision medicine paradigm.
Lung cancer remains the most prevalent and lethal form of cancer in China, placing a heavy burden on the national healthcare system. The emergence of reliable, domestically-produced companion diagnostics is critical for the widespread adoption of targeted therapies. AmoyDx’s successful registration signals the maturation of China's biotech infrastructure, moving beyond basic testing to high-stakes clinical decision support.
This approval also reflects the shifting dynamics within the global pharmaceutical landscape in China. As multinational corporations seek to navigate the Chinese market, partnerships with domestic diagnostic firms like AmoyDx are becoming essential. By integrating local diagnostic expertise with global drug pipelines, the industry is ensuring that advanced cancer treatments are both accessible and effective for the Chinese population.